FENC
Fennec Pharmaceuticals Inc
10.40$
+0.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 5.1% | 7.0% | 2.2% | 8.4% | 19.5% | 8.4% | 4.3% | 10.0% | 5.3% | 12.8% | 3.8% | 4.0% | 6.3% | |
| 94.9% | 93.0% | 97.8% | 91.6% | 80.5% | 91.6% | 95.7% | 90.0% | 94.7% | 87.2% | 96.2% | 96.0% | 93.7% | |
| 0.2% | 0.3% | 0.0% | 2.2% | 1.4% | 0.6% | 1.1% | 1.1% | 0.2% | 0.1% | 0.3% | 0.7% | 0.4% | |
| 58.4% | 71.6% | 23.1% | 94.5% | 87.8% | 52.9% | 67.0% | 72.1% | 54.2% | 61.3% | 21.1% | 26.0% | 38.9% | |
| 110.5% | 111.6% | 43.7% | 161.0% | 155.4% | 103.7% | 105.1% | 118.3% | 96.3% | 105.9% | 97.0% | 86.2% | 95.7% | |
| -15.6% | -18.7% | 54.2% | -69.4% | -74.9% | -12.1% | -9.4% | -28.3% | -1.6% | -18.7% | -0.8% | 9.7% | -2.0% | |
| 13.1% | 9.4% | 4.1% | 14.7% | 14.7% | 12.2% | 6.9% | 6.4% | 4.7% | 2.2% | 0.0% | 0.0% | 1.5% | |
| -28.7% | -27.6% | 50.6% | -76.5% | -82.2% | -20.4% | -13.3% | -32.7% | -5.1% | -34.0% | 1.3% | 11.3% | -5.2% | |
| 13.1% | 0.0% | -2.8% | 0.0% | – | 4.6% | – | – | – | 0.8% | – | 0.2% | – | |
| -28.7% | -27.6% | 50.6% | -76.5% | -82.2% | -25.0% | -13.3% | -32.7% | -5.1% | -34.7% | 1.3% | 11.0% | -5.5% | |
| -15.5% | -17.4% | 57.5% | -61.7% | -67.2% | -7.9% | -6.3% | -26.2% | -0.2% | -31.6% | 1.5% | 9.9% | -4.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.